5.2.7.3	  Alpha 1-blockers + beta-3 agonist  Mechanism of action: Combination therapy consists of an α1-blocker (Section 5.2.1) together with a beta-3-  agonist (Section 5.2.4) as an add-on therapy in males receiving α1-blockers with persisting OAB symptoms.,
Recommendations,Strength rating
Use combination treatment of a α1-blocker with a muscarinic receptor antagonist in   patients with moderate-to-severe LUTS if relief of storage symptoms has been insufficient   with monotherapy with either drug.,Strong
Do not prescribe combination treatment in men with a post-void residual volume > 150 mL.,Weak
